PriceTargets.com logo

Oxford Biomedica - OXB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: GBX 558
  • Forecasted Upside: -10.36%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 622.51 As of 12/4/2025 01:08 PM ET
▼ -5.491 (-0.87%)

This chart shows the closing price for OXB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXB

Analyst Price Target is GBX 558
▼ -10.36% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 558, with a high forecast of GBX 930 and a low forecast of GBX 400. The average price target represents a -10.36% upside from the last price of GBX 622.51.

This chart shows the closing price for OXB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Oxford Biomedica. This rating has held steady since August 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/7/2025Canaccord Genuity GroupReiterated RatingBuyGBX 451
8/26/2025Royal Bank Of CanadaBoost TargetOutperformGBX 800 ➝ GBX 930
8/1/2025Peel HuntReiterated RatingBuyGBX 451
7/15/2025JPMorgan Chase & Co.Lower TargetNeutralGBX 490 ➝ GBX 400
9/24/2024Deutsche Bank AktiengesellschaftBoost TargetHoldGBX 250 ➝ GBX 380
5/21/2024Royal Bank Of CanadaReiterated RatingOutperformGBX 740
3/20/2024Numis SecuritiesReiterated RatingHoldGBX 180
9/26/2023Liberum CapitalLower TargetHoldGBX 350 ➝ GBX 310
6/21/2023JPMorgan Chase & Co.Reiterated RatingNeutralGBX 495
5/24/2023Royal Bank Of CanadaLower TargetOutperformGBX 1,110 ➝ GBX 1,010
10/11/2022Royal Bank Of CanadaBoost TargetOutperformGBX 1,020 ➝ GBX 1,110
6/30/2022Royal Bank Of CanadaReiterated RatingOutperformGBX 1,070
6/21/2022Royal Bank Of CanadaReiterated RatingOutperformGBX 1,070
5/23/2022Royal Bank Of CanadaReiterated RatingOutperformGBX 1,070
4/20/2022Liberum CapitalReiterated RatingBuyGBX 1,380
3/24/2022Royal Bank Of CanadaReiterated RatingOutperformGBX 1,340
2/1/2022Royal Bank Of CanadaLower TargetOutperformGBX 1,450 ➝ GBX 1,340
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
5/19/2021Liberum CapitalBoost TargetBuyGBX 1,300 ➝ GBX 1,330
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Numis SecuritiesReiterated RatingBuyGBX 1,200
4/15/2021Liberum CapitalReiterated RatingBuyGBX 1,300 ➝ GBX 1,280
4/6/2021Liberum CapitalReiterated RatingBuyGBX 1,280
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Read More

Today's Range

Now: GBX 622.51
Low: 612
High: 636

50 Day Range

MA: GBX 615.87
Low: 546.31
High: 668.99

52 Week Range

Now: GBX 622.51
Low: 232.50
High: 685

Volume

620,109 shs

Average Volume

279,672 shs

Market Capitalization

£748.29 million

P/E Ratio

N/A

Dividend Yield

4.57%

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following Wall Street research analysts have issued stock ratings on Oxford Biomedica in the last year: Canaccord Genuity Group Inc., JPMorgan Chase & Co., Peel Hunt, and Royal Bank Of Canada.
View the latest analyst ratings for OXB.

What is the current price target for Oxford Biomedica?

0 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. Their average twelve-month price target is GBX 558, suggesting a possible downside of 10.4%. Royal Bank Of Canada has the highest price target set, predicting OXB will reach GBX 930 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 400 for Oxford Biomedica in the next year.
View the latest price targets for OXB.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OXB.

What other companies compete with Oxford Biomedica?

Other companies that are similar to Oxford Biomedica include Abcam, Genus, Oxford Nanopore Technologies, Ergomed and Silence Therapeutics. Learn More about companies similar to Oxford Biomedica.

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company's listed phone number is +44-1865-783000. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk. Learn More about contacing Oxford Biomedica investor relations.